Predicting liver abscess after TACE for liver cancer
Part of Cancer, Digestive system, Infections clinical trials.
This study looks at patients with liver cancer (HCC) who had a procedure called TACE (chemoembolization) after surgery. It aims to understand why some people develop a liver abscess (a pocket of infection) after TACE and how that affects their outcome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with liver cancer (HCC) and received TACE (chemoembolization) after surgery.
- If you developed a liver abscess after TACE, you may be in the case group.
- If you had TACE without developing a liver abscess, you could be in the control group.
- Your medical records must be complete and you must have been followed up after treatment.
- Only patients treated between 2009 and 2023 are included.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of CT scan (spectral CT) to see how well liver cancer has responded to a previous TACE treatment. If you've already had TACE for your liver cancer, this scan may help your doctors decide on the next steps, such as surgery or another procedure.
This trial looks at whether adding a procedure called TACE to standard immunotherapy (Atezolizumab plus Bevacizumab) works better for people with liver cancer that cannot be removed by surgery. It aims to create a model to predict who benefits most from this combination.
This study looks at how liver abscesses are treated and how well they heal. It includes people whose abscess was found on a scan and drained, and who got better with antibiotics.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
This trial tests a procedure called TACE combined with an immune-boosting step for people with liver cancer that cannot be surgically removed. The goal is to see if this combination can help control the tumor while you are already on systemic treatment.
This study is looking at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer that can't be removed by surgery. The goal is to learn how to predict the best response using lab tests and CT scans.
Hear when a new TACE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.